Completed PHASE2 INTERVENTIONAL 1-arm NCT01006044

Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection

Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra

Conditions Glioblastoma Multiforme

Interventions autologous dendritic cells

Updated 5 times since 2017 Last updated: Sep 2, 2014 Started: Oct 31, 2009 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Glioblastoma Multiforme and is currently completed. Clinica Universidad de Navarra, Universidad de Navarra leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinica Universidad de Navarra, Universidad de Navarra

Data source: Clinica Universidad de Navarra, Universidad de Navarra

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pamplona, Spain